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Recent reports from pulmonary arterial hypertension 
(PAH) registries suggest that the mean age at diagnosis is 
increasing in a growing proportion of elderly patients.[1–6] 
The combination of several reasons such as aging popula-
tion, increase in life expectancy, growing PAH awareness of 
physicians and patients, and availability of more treatment 
options could explain the changing picture of PAH. PAH 
should be considered as an emerging entity in the elderly. 
Elderly PAH patients suffer from severe pulmonary vascu-
lar disease with a poor survival rate.[7] This population has 
an increased likelihood of comorbidities or physiological 
age-related changes that could make PAH diagnosis chal-
lenging. Diagnostic workup of severe pulmonary hyperten-
sion (PH) in the elderly should be performed in such a way 
as to discriminate between the expected consequences of 
aging, pulmonary vascular disease, and other frequent caus-
es of secondary PH (left heart disease or lung disease). 
Careful evaluation by right heart catheterization (RHC) is 
mandatory. The progressive decline in lung function with 
normal aging has been demonstrated.[8] A decrease in left 
heart compliance is also observed.[9] Systolic pulmonary 
artery pressure (sPAP) estimated by Doppler echocardi-
ography shows a significant age-related increase of 
approximately 1 mmHg per decade.[10] Age-related physio-
logical changes of the cardiovascular and respiratory sys-
tems should be kept in mind when PH is suspected in the 
elderly. PAH could be suspected in the elderly who pre-
sent hemodynamic and clinical alterations “out of propor-
tion to age” with very unusually elevated pulmonary vas-
cular resistance (PVR) and mean pulmonary artery pressure 
(mPAP).  
Chronic obstructive pulmonary disease (COPD) can lead 
to PH. Severe PH rarely occurs in stable COPD patients.[11] 
When disproportionate PH is suspected in COPD, confir-
mation by RHC should be performed. Potential associated 
conditions should be considered because they could be eas-
ily treatable.[11] Further studies evaluating the pathobiology 
of PH in COPD and characterizing the phenotype of the 
combination of a rare disease (PAH or PAH-like) and a very 
frequent one (COPD) are needed.  
Left heart disease is the most frequent cause of PH. Heart 
failure with preserved ejection fraction (HFpEF) PH may be 
more difficult to assess, may be associated with dyspnea or 
considered as related to aging. HFpEF PH is a major differ-
ential diagnosis of PAH. Some patients with HFpEF could 
be missed. In this condition, the transpulmonary gradient 
(TPG) is low (≤ 12 mmHg) and PH is considered as passive. 
TPG validity has been recently challenged.[12] In the elderly, 
the increased stiffness of the pulmonary vessels may indeed 
lead to a disproportionate increase in sPAP. Elevated left 
ventricle (LV) filling pressure and diminished pulmonary 
vascular recruitment may lead to elevated TPG, erroneously 
suggesting a precapillary component. Supplementary pa-
rameters such as elevated PVR or diastolic pulmonary gra-
dient should be considered to better assess the real precapil-
lary component of Group 2 PH.[13] HFpEF could be un-
masked by fluid challenge in patients with normal pulmo-
nary capillary wedge pressure and suspected diastolic dys-
function.[14] The so-called precapillary component might not 
be that clear-cut in this subset of patients. PAH and 
HFpEF-PH could be more accurately differentiated by using 
predictive modeling. Advanced age, the presence of hyper-
tension and coronary heart disease, the absence of right atri-
al enlargement, higher aortic systolic pressure, higher mean 
right atrial pressure, and higher cardiac output best 
differentiated one from another. It is plausible to adequately 
evaluate and hemodynamically investigate elderly patients 
with severe unexplained PH in detail in expert cen- 
ter. Data from the French registry showed that the delay 
between first exposure and PAH diagnosis ranged between 
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5 and 12 years, suggesting that new incident cases can be 
expected in the next years and that one should identify 
whether a toxic exposure may have acted as a trigger for 
PAH when taking PH history, particularly in the elderly. 
With regard to the evaluation of elderly patients and the 
mandatory elements that have to be fulfilled to confirm 
PAH, hemodynamic parameters assessed by RHC should be 
examined carefully. Consistent with some of the age-related 
physiological changes, mPAP may be expected ≥ 25 mmHg 
in 1 in 250 healthy subjects aged ≥ 50 years, whereas it can 
be seen in only 1 in 5000 younger ones.[7] 
Discrimination between precapillary and postcapillary 
might not be that simple. Reliance on pulmonary artery 
wedge pressure (PAWP) rather than left ventricular end 
diastolic pressure (LVEDP) in patients with suspected ele-
vated left filling pressure may result in misdiagnosis of 
PAH. When left heart catheterization (LHC) measurement 
is not available, discrepancies with LVEDP could be re-
duced by careful analysis of the RHC acquisition curves and 
PAWP values determined at the end of the respiratory cycle 
instead of a digitized calculated mean.[15] This is an impor-
tant issue, especially regarding PAH evaluation in the eld-
erly. It is reasonable and probably mandatory to consider 
LVEDP measurement by LHC in patients where HFpEF- 
PH must be ruled out. One should also remember that mild 
diastolic dysfunction is a common condition in older pa-
tients that could lead to unduly rule out PAH. Thus, elderly 
patients with suspicion of PAH should be referred to an 
expert PH center for a precise hemodynamic evaluation and 
an appropriate diagnosis. 
PAH-specific therapy is widely accepted for many pa-
tients with group 1 PAH, who have World Health Organiza-
tion (WHO) functional class II, III, or IV. In contrast, it 
should only be administered on a case-by-case basis for pa-
tients with group 3 PH, group 4 PH, or group 5 PH. PAH- 
specific therapy should not be administered to most patients 
with group 2 PH.[16,17] The evidence supporting PAH-spe-
cific therapy comes primarily from studies that included 
patients with idiopathic PAH or scleroderma-related PAH. 
It could be hypothesized that targeting precapillary HFpEF- 
PH patients with PAH-specific therapy may be rational. 
However, there is currently a lack of evidence supporting 
the role of drugs that could even be deleterious to patients 
with other forms of PH. However, there are a few situations 
in which PAH-specific therapy may be considered for group 
2 PH (e.g., patients with persistent PH due to mitral valve 
disease who have undergone mitral valve replacement with 
normalization of left atrial pressure).[18] Shujaat, et al.[19] 
performed a retrospective chart review of consecutive pa-
tients with non-WHO group 1 PH treated with PAH-specific 
therapy. The 6-minute walk distance (6-MWD) improved 
significantly only in patients with obstructive sleep apnea 
(OSA) or patients with severe PH.[19] Therefore, the use of 
PAH-specific therapy in selected patients with non-WHO 
group I PH may result in significant improvement in 
6-MWD, particularly in patients with OSA or severe PH.          
There is no single best approach to selecting an agent for 
PAH-specific therapy. Initial monotherapy or combination 
therapy, and sequential combination therapy could be con-
sidered based on multiple factors including WHO functional 
class, right ventricular function, hemodynamics, vasoreac-
tivity test, patient characteristics and preferences, and coun-
try and regional variations.[16,17,20] Whether sequential com-
bination therapy results in similar long-term benefits com-
pared with initial combination therapy is not known. Clini-
cians with expertise in the treatment of patients with PAH 
may also individualize therapy based on their clinical ex-
perience. For patients in class II and III with a new diagno-
sis of PAH, many experts initially administer oral agents 
that target the endothelin and nitric oxide-cyclic guanosine 
monophosphate pathways in combination. The combination 
of ambrisentan and tadalafil is preferred because it is asso-
ciated with a significant reduction in the rate of clinical fail-
ure compared to monotherapy with either drug alone. For 
those who have a contraindication to either agent, substitu-
tion with another oral agent in the same class is preferred, 
although such combinations are less well proven and drug 
interactions can potentially limit the outcome. 
The elderly candidate for PAH-specific therapy should 
be selected by experienced clinicians and must be based 
upon an appropriately established diagnosis and evaluation 
of the patient’s disease severity. The options for pharmaco-
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